Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival

Cancer Research

Volumn 66, Issue 8, 2006, Pages 4319-4328

  Subramanian, Indira V ^a   Nguyen, Tri Minh Bui ^a   Truskinovsky, Alexander M ^a   Tolar, Jakub ^a   Blazar, Bruce R ^a   Ramakrishnan, Sundaram ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CARBOPLATIN; ENDOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ENDOSTATINS; FEMALE; GENE THERAPY; HUMANS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646242264     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3297     Document Type: Article

References (41)

1. Jemal A, Murray T, Samuels A, Ghafoor A. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Oriel KA, Hartenbach EM, Remington PL. Trends in United States ovarian cancer mortality, 1979-1995. Obstet Gynecol 1999;93:30-3.
3. Leung EH, Leung PC, Auersperg N. Differentiation and growth potential of human ovarian surface epithelial cells expressing temperature-sensitive SV40 T antigen. In Vitro Cell Dev Biol Anim 2001;37:515-21.
4. International Federation of Gynecology and Obstetrics. Changes in clinical definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:46.
5. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998;78:1479-87.
6. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994;54:276-80.
7. Yoneda J, Kuniyasu H, Crispens MA, et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90:447-54.
8. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996;22:237-9.
9. Hartenbach EM, Olson TA, Goswitz JJ, et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997;121:169-75.
10. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer (Phila) 1997;80:98-106.
11. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-8.
12. Luo JC, Yamaguchi S, Shinkai A, et al. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res 1998;58:2652-60.
13. Wild R, Dings RPM, Subramanian I, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 2004;110:343-51.
14. Calvo A, Yokoyama Y, Smith LE, et al. Inhibition of the mammary carcinoma angiogenic switch in C3 (1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 2002;101:224-34.
15. Yokoyama Y, Ramakrishnan S. Improved biological activity of mutant endostatin containing a single amino acid substitution. Br J cancer 2004;90:1627-35.
16. Subramanian IV, Ghebre R, Ramakrishnan S. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther 2005;12:30-8.
17. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tcl-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-10.
18. Sauer MG, Ericson ME, Weigel BJ, et al. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo -generated leukemia-reactive cytotoxic t cells. Cancer Res 2004;64:3914-21.
19. Tolar J, Osborn M, Bell S, et al. Real-time in vivo imaging of stem cells following transgenesis by transposition. Mol Ther 2005;12:42-8.
20. Wild R, Ramakrishnan S, Sedgewick J, Griffloen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000;59:368-6.
21. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60:6253-8.
22. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-6.
23. Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:901-18.
24. Mahasreshti PJ, Navarro JG, Kataram M, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma Clin Cancer Res 2001;7:2057-66.
25. Yokoyama Y, Ramakrishnan S. Addition of integrin-binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer 2004;111:839-48.
26. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
27. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
28. Lai G, Ozols JF, Smyth RC, Young C, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988;37:4597-600.
29. Bao R, Selvakumaran M, Hamilton TC. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. Gynecol Oncol 2000;78:373-9.
30. Nilsson EE, Westfall SD, McDonald C, et al. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics. Cancer Chemother Pharmacol 2002;49:93-100.
31. Connolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63:1389-97.
32. Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004;64:1781-7.
33. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 2003;66:1-9.
34. Indraccolo S, Minuzzo S, Gola E, et al. Generation of expression plasmids for angiostatin, endostatin, and TIMP-2 for cancer gene therapy. Int J Biol Markers 1999;14:251-6.
35. Isayeva T, Ren C, Ponnazhagan S. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer. Clin Cancer Res 2005;11:1342-7.
36. Mahendra G, Kumar S, Isayeva T, et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther 2005;12:26-34.
37. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
38. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
39. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992;52:6702-4.
40. Harries M, Kaye SB. Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs 2001;10:1715-24.
41. Tattersall MHN. Ovarian cancer chemotherapy: carboplatin as standard. Lancet 2002;360:500-1.